Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects
NCT ID: NCT00551031
Last Updated: 2016-05-16
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
2098 participants
INTERVENTIONAL
2007-10-31
2008-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Primary Objective:
To demonstrate non-inferiority of post-vaccination immunogenicity of subjects who received either 1 of the 2 investigational formulations of a trivalent inactivated vaccine (TIV) compared to that of the standard Fluzone® in elderly subjects.
Secondary Objectives:
Immunogenicity To describe the immunogenicity in subjects receiving investigational Fluzone and standard Fluzone®.
Safety:
To evaluate and describe the safety profile of investigational Fluzone in terms of solicited- and unsolicited adverse events and serious adverse events post-vaccination.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects
NCT00388583
Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly
NCT00391053
Elderly Influenza Vaccine Immunogenicity Substudy
NCT00170482
Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults
NCT00772109
Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Infants and Children
NCT00391391
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Influenza Virus Vaccine Formulation 1
Influenza Virus Vaccine Formulation 1
Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1)
0.1 mL, Intradermal (ID)
Influenza Virus Vaccine Formulation 2
Influenza Virus Vaccine Formulation 2
Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2)
0.1 mL, Intradermal (ID)
Fluzone® Elderly Group
Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)
0.5 mL, Intramuscular (IM)
Fluzone® High-dose Group
Participants enrolled at age ≥ 65 years
Split, Inactivated, Trivalent Influenza Vaccine (High-dose)
0.5 mL, Intramuscular (IM)
Fluzone® Adults Group
Participants enrolled at age 18-49 years.
Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)
0.5 mL, Intramuscular (IM)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1)
0.1 mL, Intradermal (ID)
Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2)
0.1 mL, Intradermal (ID)
Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)
0.5 mL, Intramuscular (IM)
Split, Inactivated, Trivalent Influenza Vaccine (High-dose)
0.5 mL, Intramuscular (IM)
Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)
0.5 mL, Intramuscular (IM)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Informed consent form signed.
* Medically stable (Subjects may have underlying illnesses such as hypertension, diabetes, ischemic heart disease or hypothyroidism, as long as their symptoms/signs are controlled. If they are on medication for a condition, the medication dose must have been stable for at least 3 weeks preceding vaccination.
* Able to attend all scheduled visits and to comply with all trial procedures.
* For a woman of child-bearing potential, avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to vaccination, until at least 4 weeks after vaccination
Exclusion Criteria
* Known or suspected congenital or acquired immunodeficiency, hepatitis B (HBsAg) or hepatitis C infection or seropositivity immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy
* For a woman of child-bearing potential, known pregnancy or positive urine pregnancy test.
* Breast feeding woman.
* Neoplastic disease or any hematologic malignancy, (except localized skin or prostate cancer that is stable at the time of vaccination in the absence of therapy, as well as subjects who have a history of neoplastic disease and who have been disease free for ≥ 5 years).
* Current use of alcohol or recreational drugs that in the opinion of the Investigator may interfere with the subject's ability to comply with trial procedures.
* Receipt of blood or blood-derived products in the past 3 months that might interfere with the assessment of immune response.
* Vaccination against influenza in the past 6 months.
* Any vaccination in the 4 weeks preceding the trial vaccination.
* Planned receipt of any other vaccine in the four weeks following the trial vaccination.
* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding trial vaccination.
* Planned participation in another clinical trial during the present trial period.
Note: Concomitant participation in an observational trial (not involving drugs, vaccines, or medical devices) is acceptable.
* Known thrombocytopenia or bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating intramuscular vaccination.
* Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the investigator
* Personal or family history of Guillain-Barré Syndrome.
* Known current human immunodeficiency virus (HIV), hepatitis B (HBsAg) or hepatitis C infection or seropositivity.
* Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent.
* An acute febrile illness \[oral temperature ≥ 99.5°F (≥ 37.5°C)\] within 24 hours prior to vaccination. If this exists, vaccination will be deferred until the participant becomes afebrile.
* Signs and symptoms of an acute infectious respiratory illness. If this exists, vaccination will be deferred until the symptoms resolve.
* The use of an antibiotics therapy within 72 hours preceding the trial vaccination. If this exists, vaccination will be deferred until at least 72 hours after the last antibiotics therapy.
* Receipt of any allergy shots in the 7-day period prior to enrollment (vaccination), or scheduled to receive any allergy shots in the 7-day period after enrollment (vaccination). Subjects should be enrolled in the trial only if their allergy shots are given on a stable schedule outside the 7-day periods pre- and post-vaccination.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanofi
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director
Role: STUDY_DIRECTOR
Sanofi Pasteur Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alabaster, Alabama, United States
Mobile, Alabama, United States
Chandler, Arizona, United States
Mesa, Arizona, United States
Phoenix, Arizona, United States
Tucson, Arizona, United States
Fountain Valley, California, United States
San Diego, California, United States
Stanford, Connecticut, United States
Pembroke Pines, Florida, United States
Pinellas Park, Florida, United States
Boise, Idaho, United States
Chicago, Illinois, United States
Wichita, Kansas, United States
Kansas City, Missouri, United States
Springfield, Missouri, United States
St Louis, Missouri, United States
Cary, North Carolina, United States
Raleigh, North Carolina, United States
Cincinnati, Ohio, United States
Allentown, Pennsylvania, United States
Bensalem, Pennsylvania, United States
Warwick, Rhode Island, United States
Goose Creek, South Carolina, United States
Fort Worth, Texas, United States
Galveston, Texas, United States
Salt Lake City, Utah, United States
West Jordan, Utah, United States
Marshfield, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tsang P, Gorse GJ, Strout CB, Sperling M, Greenberg DP, Ozol-Godfrey A, DiazGranados C, Landolfi V. Immunogenicity and safety of Fluzone((R)) intradermal and high-dose influenza vaccines in older adults >/=65 years of age: a randomized, controlled, phase II trial. Vaccine. 2014 May 1;32(21):2507-17. doi: 10.1016/j.vaccine.2013.09.074. Epub 2013 Oct 11.
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FID29
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.